Table 3. Correlation between methylation of RUNX3 promoter and clinicopathological characters in NSCLC.
| NO. study | Characters | M+/M– | OR (95% CI) | I2 (%) | P (Egger’ test) | |
|---|---|---|---|---|---|---|
| 6 | Gender | Male | 73/156 | 0.80 (0.51-1.26)b | 0.8 | 0.054 |
| Female | 57/116 | |||||
| 5 | Smoking | Yes | 52/133 | 0.64 (0.38-1.07)b | 25.2 | 0.438 |
| No | 53/102 | |||||
| 9 | Pathological type | ACC/SCC | 102/201; 44/180 | 2.25 (1.48-3.42)b | 34.3 | 0.135 |
| 5 | ACC/other type | 46/124; 18/18 | 0.49 (0.22-1.10)b | 0 | 0.595 | |
| 5 | SCC/other type | 21/106; 18/9 | 0.10 (0.04-0.29)b | 0 | 0.068 | |
| 3 | Differentiation | H/M | 40/68 | 0.39 (0.06-2.36)a | 86.4 | 0.276 |
| P | 41/33 | 0.47 (0.26-0.85)b | ||||
| 6 | TNM stage | I-II | 58/151 | 0.79 (0.24-2.62)a | 78.3 | 0.953 |
| III-IV | 69/105 | |||||
M+, the number of tissues with methylation; M–, the number of tissues with unmethylation; other type, large-cell carcinoma and adenosquamous cell carcinoma. H/M, highly and moderately differentiated; P, poor differentiation. a, by random effect model (DerSimonian-Laird method); b, by fixed effects model (Mantel-Haenszel). Abbreviations: RUNX3, runt-related transcription factor 3; SCC, squamous cell carcinoma; ACC, adenocarcinoma; NSCLC, non-small cell lung cancer; OR, odds ratio; CI, confidence interval.